Infections and IBD

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 5, Issue 1, 2008, Pages 18-27

  Irving, Peter M ^a   Gibson, Peter R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIPARASITIC AGENT; CORTICOSTEROID; CYCLOSPORIN A; GANCICLOVIR; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISONIAZID; LAMIVUDINE; METHOTREXATE; NATALIZUMAB; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY; VIRUS ANTIGEN; VIRUS DNA;

ABSCESS; ANUS FISTULA; ASPERGILLOSIS; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; COLON BIOPSY; COLON RESECTION; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG FATALITY; DRUG SAFETY; ENTERITIS; HEPATITIS B; HISTOPATHOLOGY; HISTOPLASMOSIS; HOOKWORM INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFECTION; INFECTION RISK; INFECTION SENSITIVITY; INNATE IMMUNITY; LISTERIOSIS; MALNUTRITION; MYCOSIS; NOCARDIOSIS; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PERIANAL ABSCESS; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; RISK REDUCTION; SCREENING TEST; SIDE EFFECT; TRICHURIASIS; TUBERCULOSIS; ULCERATIVE COLITIS; VIRUS CULTURE; VIRUS IDENTIFICATION; VIRUS INFECTION;

BACTERIAL INFECTIONS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNOCOMPETENCE; RISK FACTORS; VIRUS DISEASES;

EID: 38048999633     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep1004     Document Type: Review

References (73)

1. Ohkusa T, Nomura T, Sato N (2004) The role of bacterial infection in the pathogenesis of inflammatory bowel disease. Intern Med 43: 534-539
2. Shanahan F, O'Mahony J (2005) The mycobacteria story in Crohn's disease. Am J Gastroenterol 100: 1537-1538
3. Gibson PR (1997) Ulcerative colitis: An epithelial disease? Baillieres Clin Gastroenterol 11: 17-33
4. Ryan P et al. (2004) Bacterial DNA within granulomas of patients with Crohn's disease - detection by laser capture microdissection and PCR. Am J Gastroenterol 99: 1539-1543
5. Ryan P et al. (2002) PCR detection of Mycobacterium paratuberculosis in Crohn's disease granulomas isolated by laser capture microdissection. Gut 51: 665-670
6. Nuding S et al. (2007) Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut 56: 1240-1247
7. Hugot JP et al. (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411: 599-603
8. Marks DJ et al. (2006) Defective acute inflammation in Crohn's disease: A clinical investigation. Lancet 367: 668-678
9. Vignal C et al. (2007) How NOD2 mutations predispose to Crohn's disease? Microbes Infect 9: 658-663
10. Peyrin-Biroulet L and Chamaillard M (2007) NOD2 and defensins: translating innate to adaptive immunity in Crohn's disease. J Endotoxin Res 13: 135-139
11. Powell SJ and Wilmot AJ (1966) Ulcerative post-dysenteric colitis. Gut 7: 438-443
12. Garcia Rodriguez LA et al. (2006) Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology 130: 1588-1594
13. Schumacher G et al. (1993) A prospective study of first attacks of inflammatory bowel disease and non-relapsing colitis. Microbiologic findings. Scand J Gastroenterol 28: 1077-1085
14. Mylonaki M et al. (2004) Enteric infection in relapse of inflammatory bowel disease: Importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 16: 775-778
15. Issa M et al. (2007) Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 5: 345-351
16. Rodemann J F et al. (2007) Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 5: 339-344
17. Abbas MA et al. (2000) Colonic perforation in unsuspected amebic colitis. Dig Dis Sci 45: 1836-1841
18. Bertalot G et al. (2001) Evidence of Epstein-Barr virus infection in ulcerative colitis. Dig Liver Dis 33: 551-558
19. Hommes DW et al. (2004) The pathogenicity of cytomegalovirus in inflammatory bowel disease: A systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis 10: 245-250
20. Kandiel A and Lashner B (2006) Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 101: 2827-2865
21. Hommes DW (2006) CMV co-infection - does it matter? In Clinical Dilemmas in Inflammatory Bowel Disease, 159-163 (Eds Irving PM et al.) Oxford, UK: Blackwell
22. Criscuoli V et al. (2004) Severe acute colitis associated with CMV: A prevalence study. Dig Liver Dis 36: 818-820
23. Papadakis KA et al. (2001) Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol 96: 2137-2142
24. Matsuoka K et al. (2007) Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol 102: 331-337
25. Samuel S and Mahida YR (2006) Intestinal infections: Mimics and precipitants of relapse. In Clinical Dilemmas in Inflammatory Bowel Disease, 217-221 (Eds Irving P et al.) Oxford: Blackwell
26. Winther KV et al. (2003) Survival and cause-specific mortality in ulcerative colitis: Follow-up of a population-based cohort in Copenhagen County. Gastroenterology 125: 1576-1582
27. Jess T et al. (2002) Mortality and causes of death in Crohn's disease: Follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology 122: 1808-1814
28. Ben Ami H et al. (2002) Diagnosis and treatment of urinary tract complications in Crohn's disease: An experience over 15 years. Can J Gastroenterol 16: 225-229
29. Pirlich M et al. (2003) Prevalence of malnutrition in hospitalized medical patients: Impact of underlying disease. Dig Dis 21: 245-251
30. O'Sullivan M and O'Morain C (2006) Nutrition in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 20: 561-573
31. Scrimshaw NS (2003) Historical concepts of interactions, synergism and antagonism between nutrition and infection. J Nutr 133: 316S-321S
32. Camus P and Colby TV (2000) The lung in inflammatory bowel disease. Eur Raspir J 15: 5-10
33. Gelzayd EA et al. (1968) Nephrolithiasis in inflammatory bowel disease. Am J Dig Dis 13: 1027-1034
34. Fausa O et al. (1991) Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 11: 31-39
35. Melmed GY et al. (2006) Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 101: 1834-1840
36. Sands BE et al. (2004) Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 10: 677-692
37. Sanchez-Fructuoso Al et al. (2000) Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: Mycophenolate versus azathioprine. Transplantation 69: 436-439
38. Dotan I et al. (2007) Azathioprine (AZA)/6-mercaptopurine (6MP) therapy has no significant effect on cellular or humoral immune responses in patients with inflammatory bowel disease. Gastroenterology 4 (Suppl 2): A51
39. Lichtenstein GR et al. (2006) Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4: 621-630
40. Stuck AE et al. (11989) Risk of infectious complioations in patients taking glucocorticosteroids. Rev Infect Dis 11 954-963
41. Connell WR et al. (1993) Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34: 1081-1085
42. Lamers CB et al. (1999) Azathioprine: An update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol Suppl 230: 111-115
43. Present DH et al. (1989) 6-Mercaptopurine in the management of inflammatory bowel disease: Short-and long-term toxicity. Ann Intern Med 111: 641-649
44. Bernatsky S et al. (2007) Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 46: 1157-1160
45. Toruner M et al. (2006) Risk factors for opportunistic infections in inflammatory bowel diseases: A case-control study. Gastroenterology 130 (Suppl 2): 96
46. 2007 Periodic Safety Update Report (PSUR): Infliximab. April
47. Wallis R.S et al. (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38: 1261-1265
48. Irving PM et al. (2007) Review article: Appropriate use of corticosteroids in Crohn's disease. Aliment Pharmacol Ther 26 313-329
49. Carmona L et al. (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52: 1766-1772
50. Hernandez-Cruz B et al. (1999) Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases. A case-control study. Clin Exp Rheumatol 17: 81-87
51. Winthrop KL (2006) Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2: 602-610
52. Slifman NR et al. (2003) Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 48: 319-324
53. Nathan DM et al. (2006) Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: Guidelines for clinical approach J Gastroenterol Hepatol 21: 1366-1371
54. Arts J et al. (2004) Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 10: 73-78
55. Farthing MJG (2003) Infectious colitis. In Inflammatory Bowel Disease: From Bench to Bedside, 845-861 (Eds Targan S et al.) New York: Springer
56. Malchow H et al. (1984) European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment. Gastroenterology 86: 249-266
57. Sands BE et al. (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350: 876-885
58. Mayberry J and Mann R (1989) Inflammatory bowel disease in rural sub-Saharan Africa: Rarity of diagnosis in patients attending mission hospitals. Digestion 44: 172-176
59. Gent AE et al. (1994) Inflammatory bowel disease and domestic hygiene in infancy. Lancet 343: 766-767
60. Summers RW et al. (2003) Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol 98: 2034-2041
61. Summers RW et al. (2005) Trichuris suis therapy for active ulcerative colitis: A randomized controlled trial. Gastroenterology 128: 825-832
62. Summers RW et al. (2005) Trichuris suis therapy in Crohn's disease. Gut 54: 87-90
63. Croese J et al. (2006) A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors. Gut 55: 136-137
64. Shin JL et al. (2004) Does whipworm increase the pathogenicity of Campylobacter jejuni? A clinical correlate of an experimental observation. Can J Gastroenterol 18: 175-177
65. Kradin RL et al. (2006) latrogenic Trichuris suis infection in a patient with Crohn disease. Arch Pathol Lab Med 130: 718-720
66. Summers RW et al. (2006) Therapeutic colonization with Trichuris suis. Arch Pathol Lab Med 130: 1753-1754
67. Sartor RB (2005) Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol 21: 44-50
68. Ewaschuk JB and Dieleman LA (2006) Probiotics and prebiotics in chronic inflammatory bowel diseases. World J Gastroenterol 12: 5941-5950
69. Bongartz T et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275-2285
70. Colombel JF et al. (2004) The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients. Gastroenterology 126: 19-31
71. Esteve M et al. (2004) Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: Need for primary prophylaxis. Gut 53: 1363-1365
72. Ghosh S et al. (2003) Natalizumab for active Crohn's disease. N Engl J Med 348: 24-32
73. Van Assche G et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362-368